Posted by Michael Wonder on 15 Oct 2021
Highlights from CHMP 11-14 October 2021 meeting
15 October 2021 - EMA’s CHMP recommended six medicines for approval at its October 2021 meeting.
Trodelvy (sacituzumab govitecan) was granted a positive opinion for the treatment of unresectable or metastatic triple negative breast cancer.
